Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.

Abstract excerpt

Mutations in the BRAF oncogene are found in 2-4% of all non-small cell lung cancer (NSCLC) patients. The most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within the BRAF kinase. BRAF-targeted therapies are effective in patients with melanoma and NSCLC harboring BRAF V600E mutation. In both melanoma and NSCLC, dual...

Topics

Join the communities discussing this publication.

• Antineoplastic Combined Chemotherapy Protocols
• Imidazoles
• MAP Kinase Kinase Kinases
• Oximes
• Protein Kinase Inhibitors